In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost ~28.7% of body weight (~71 lbs at 68 weeks) and saw substantial improvements in pain and function: WOMAC pain scores reduced by 4.5 points (75.8%) Meaningful gains in physical function, with many patients essentially free of knee pain by study end If these results are confirmed in broader use, were not just talking about weight loss drugs anymorewere talking about disease-modifying therapies that simultaneously target obesity, pain, mobility, and downstream CV risk
When it comes to losing weight, its important to have realistic goals
The glucagon component increases energy expenditure
Your individual risk depends on factors like dosage, treatment duration, underlying health conditions, and lifestyle habits
How soon after gastric sleeve surgery can I start GLP-1 medications
Treating multiple zones creates a cohesive result